yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
Today's Top SOA Links

Aratana Therapeutics Expands Senior Management Team with Appointment of Julia A. Stephanus as Chief Commercial Officer

KANSAS CITY, Kan. and NEW YORK, Jan. 15, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced it has appointed an experienced animal health executive Julia A. Stephanus as Chief Commercial Officer, as part of a recent strategic expansion of the senior management team.  Ms. Stephanus is a commercial leader in veterinary pharmaceuticals and Aratana expects to leverage her significant marketing and commercialization expertise as the Company continues advancing its pipeline of companion animal medicines.

Ms. Stephanus has more than 25 years of animal health marketing experience.  Throughout her career, she has developed and successfully launched new products for companion animals, including innovative first-in-class products such as Rimadyl®, the first NSAID approved for osteoarthritis in dogs, and Revolution®, the first topical endectocide for heartworm and fleas in dogs and cats.  In her most recent role at Ceva Animal Health, she led the companion animal franchise, overseeing the commercial development of new products as well as global marketing for strategic companion animal products.  

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, stated, "As we look ahead to Aratana's future success as a premier animal health partner and provider of innovative medicines for companion animals, we are very happy to add Julia to lead our commercial team.  Her 'brand-builder' philosophy and proven track record for marketing successful products will be critical for Aratana as we advance our pipeline and begin positioning our products for commercialization."

Ms. Stephanus stated, "Aratana has built a strong pipeline of companion animal medicines that fulfill significant unmet needs in the market.  I look forward to developing and marketing these innovative therapies, as well as helping to expand the current product pipeline by adding new assets that have significant market potential."

Julia A. Stephanus
Prior to joining Aratana, Ms. Stephanus was Director of the Companion Animal Global Franchise for Ceva Animal Health, a role she assumed following the acquisition of Summit VetPharm by Ceva in 2010.  Ms. Stephanus founded Summit VetPharm in 2005 where she developed and launched Vectra®, a new companion animal parasiticide product line.  Following the acquisition, Ms. Stephanus transitioned the business and continued building and expanding Vectra, which is expected to become a $100+ million blockbuster global brand.

Prior to founding Summit VetPharm, Ms. Stephanus worked in various sales and marketing positions for Pfizer and its legacy companies, where she had the commercial responsibility for the development and global launch of two blockbuster companion animal products (Rimadyl® and Revolution®), as well as numerous other pharmaceuticals and biologicals.   Ms. Stephanus graduated from Indiana University with a B.A., and has continued her executive training at top institutions, including Harvard, Columbia, and the Wharton School of Business.

About Aratana Therapeutics

Aratana Therapeutics is a biopharmaceutical company positioned to deliver high quality new medicines that address significant therapeutic needs for cats and dogs (companion animals).  Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then develops strategies to maximize the value of the programs for the animal health market.  For more information, please visit

For Investors & Media:
Joshua Drumm, Ph.D. / Andrew Mielach
Tiberend Strategic Advisors, Inc.
(212) 827-0020

SOURCE Aratana Therapeutics

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
DevOps Summit at Cloud Expo 2014 Silicon Valley was a terrific event for us. The Qubell booth was crowded on all three days. We ran demos every 30 minutes with folks lining up to get a seat and usually standing around. It was great to meet and talk to over 500 people! My keynote was we...
Are you a winner? Are you someone who always gets what they want? Are you one of those people who do what they set their eyes on no matter what the circumstances? If you answered yes to all of these questions then you are among the highly successful people in the world that have a prov...
The iPad sales are down, but it is now possible to run most business apps on the iPad with the Citrix X1 Mouse. Can this make the iPad more relevant for business? Despite the mostly positive financial news from Apple, the one weakness that gets a lot of press is the decrease in iPad s...
Forbes called 2015, the Year of the Mobile Beacon. AdWeek talks about how beacons are already influencing the way we network, get drunk, vacation, shop, and even how we buy sausage. Ten experts at Marketing Land predicted that this year the whole world of mobile marketing will become ...
Ever wondered if your marketing efforts for an in-store sale or event are impacting, or even reaching, your customers? Foot traffic is a great indicator of marketing effectiveness. By comparing foot traffic before, during and after sale promotions you’re able to identify if any increas...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers